N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants - PubMed (original) (raw)
N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants
F M Dautzenberg et al. J Neuroendocrinol. 1999 Dec.
Abstract
Three full-length cDNAs encoding functional splice variants of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1) were isolated from Y-79 retinoblastoma cells and human cerebellum. Although the third intracellular loops of the three splice variants were identical, their N-terminal extracellular domains differed. The first full-length PAC1 variant, PAC1normal (PAC1n), encoded the entire N-terminus, whereas the second variant named PAC1short (PAC1s) was deleted by 21 amino acids (residues 89-109). Finally, the third variant, named PAC1very short (PAC1vs), was deleted by 57 amino acids (residues 53-109). Using semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis, it was established that all three variants were expressed in neuronal tissues. Binding- and cAMP studies using human embryonic kidney 293 (HEK293) cells stably transfected with PAC1n, PAC1s and PAC1vs showed significant differences in the affinities and selectivities towards PACAP38, PACAP27 and VIP. PAC1n bound PACAP38 and PACAP27 with affinities in the low nanomolar range whereas VIP was bound with up to 400-fold lower affinity. PAC1vs preferentially bound PACAP38 (Ki=121 nM) and PACAP27 (Ki=129 nM) over VIP (Ki>1000 nM) but with 100-fold lower affinity than PAC1n. Surprisingly, PAC1s unselectively bound all three ligands with high affinity. These data indicate that residues 53-88 within the N-terminal domain of the PAC1 are important for high affinity ligand binding, whereas residues 89-109 determine the receptor's ligand selectivity.
Similar articles
- Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance.
Alexandre D, Vaudry H, Grumolato L, Turquier V, Fournier A, Jégou S, Anouar Y. Alexandre D, et al. Endocrinology. 2002 Jul;143(7):2680-92. doi: 10.1210/endo.143.7.8880. Endocrinology. 2002. PMID: 12072402 - Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta.
Scaldaferri ML, Modesti A, Palumbo C, Ulisse S, Fabbri A, Piccione E, Frajese G, Moretti C. Scaldaferri ML, et al. Endocrinology. 2000 Mar;141(3):1158-67. doi: 10.1210/endo.141.3.7346. Endocrinology. 2000. PMID: 10698193 - Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB, Dejda A, Niewiadomski P, Gozes I, Nowak JZ. Zawilska JB, et al. J Mol Neurosci. 2005;25(3):215-24. doi: 10.1385/JMN:25:3:215. J Mol Neurosci. 2005. PMID: 15800375 - [Pituitary adenylate cyclase-activating polypeptide].
Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H. Gonzalez BJ, et al. Ann Endocrinol (Paris). 1998 Dec;59(5):364-405. Ann Endocrinol (Paris). 1998. PMID: 9949891 Review. French. - [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H. Hashimoto H. Yakugaku Zasshi. 2002 Dec;122(12):1109-21. doi: 10.1248/yakushi.122.1109. Yakugaku Zasshi. 2002. PMID: 12510388 Review. Japanese.
Cited by
- Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine.
Ashina H, Christensen RH, Hay DL, Pradhan AA, Hoffmann J, Reglodi D, Russo AF, Ashina M. Ashina H, et al. Nat Rev Neurol. 2024 Sep 10. doi: 10.1038/s41582-024-01011-4. Online ahead of print. Nat Rev Neurol. 2024. PMID: 39256637 Review. - Novel Fluorescently Labeled PACAP and VIP Highlight Differences between Peptide Internalization and Receptor Pharmacology.
Alexander TI, Tasma Z, Siow A, Rees TA, Brimble MA, Harris PWR, Hay DL, Walker CS. Alexander TI, et al. ACS Pharmacol Transl Sci. 2022 Dec 8;6(1):52-64. doi: 10.1021/acsptsci.2c00124. eCollection 2023 Jan 13. ACS Pharmacol Transl Sci. 2022. PMID: 36654758 Free PMC article. - PAC1, VPAC1, and VPAC2 Receptor Expression in Rat and Human Trigeminal Ganglia: Characterization of PACAP-Responsive Receptor Antibodies.
Tasma Z, Siow A, Harris PWR, Brimble MA, O'Carroll SJ, Hay DL, Walker CS. Tasma Z, et al. Int J Mol Sci. 2022 Nov 9;23(22):13797. doi: 10.3390/ijms232213797. Int J Mol Sci. 2022. PMID: 36430275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases